Trials / Completed
CompletedNCT02370524
Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Molecular NeuroImaging · Academic / Other
- Sex
- All
- Age
- 20 Years – 90 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of this exploratory imaging study is to further characterize \[18F\]T807, an investigational PET radioligand for imaging Tau (thought to be a downstream biomarker indicative of neurodegeneration in conditions such as AD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [18F]T807 | All enrolled subjects will undergo an \[18F\]T807 PET imaging visit. In addition, subjects with AD and aged volunteers will have one PET scan with Amyvid (florbetapir F 18 injection) as part of the screening activities to measure Aβ in the brain. |
Timeline
- Start date
- 2015-01-01
- Primary completion
- 2016-01-01
- Completion
- 2016-01-01
- First posted
- 2015-02-25
- Last updated
- 2017-03-08
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02370524. Inclusion in this directory is not an endorsement.